| Literature DB >> 27077873 |
Dana E Lauterstein1, Pamella B Tijerina2, Kevin Corbett3, Betul Akgol Oksuz4, Steven S Shen5,6,7, Terry Gordon8, Catherine B Klein9, Judith T Zelikoff10.
Abstract
Electronic cigarettes (e-cigarettes), battery-powered devices containing nicotine, glycerin, propylene glycol, flavorings, and other substances, are increasing in popularity. They pose a potential threat to the developing brain, as nicotine is a known neurotoxicant. We hypothesized that exposure to e-cigarettes during early life stages induce changes in central nervous system (CNS) transcriptome associated with adverse neurobiological outcomes and long-term disease states. To test the hypothesis, pregnant C57BL/6 mice were exposed daily (via whole body inhalation) throughout gestation (3 h/day; 5 days/week) to aerosols produced from e-cigarettes either with nicotine (13-16 mg/mL) or without nicotine; following birth, pups and dams were exposed together to e-cigarette aerosols throughout lactation beginning at postnatal day (PND) 4-6 and using the same exposure conditions employed during gestational exposure. Following exposure, frontal cortex recovered from ~one-month-old male and female offspring were excised and analyzed for gene expression by RNA Sequencing (RNA-Seq). Comparisons between the treatment groups revealed that e-cigarette constituents other than nicotine might be partly responsible for the observed biological effects. Transcriptome alterations in both offspring sexes and treatment groups were all significantly associated with downstream adverse neurobiological outcomes. Results from this study demonstrate that e-cigarette exposure during early life alters CNS development potentially leading to chronic neuropathology.Entities:
Keywords: RNA Sequencing; central nervous system; development; e-cigarettes; frontal cortex; nicotine; pathway analysis; transcriptome
Mesh:
Substances:
Year: 2016 PMID: 27077873 PMCID: PMC4847079 DOI: 10.3390/ijerph13040417
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1The effect of e-cigarettes on birth weight and weight gain. (a) Data represent average litter birth weights (n = 5–7 litters) ± SEM. Data were analyzed using a one-way ANOVA and Bonferroni post-hoc testing and data were not found to be significantly different from each other (F-value: 1.2, degrees of freedom: 2). (b) Data represent average litter weight gain (n = 3–5 litters) ± SEM. Data were analyzed using a two-way ANOVA and Bonferroni post hoc testing and were not found to be significantly different from each other (F-value: 0.91, degrees of freedom: 2).
Figure 2The effect of e-cigarettes with and without nicotine on global gene expression represented in terms of p-value and fold change (n = 5–6 frontal cortexes per each treatment and sex group). (a) Gene expression data for females exposed to e-cigarettes with nicotine (female controls = black, female e-cigarette with nicotine = red). (b) Gene expression data for males exposed to e-cigarettes with nicotine (male controls = black, male e-cigarette with nicotine = red). (c) Gene expression data for females exposed to e-cigarettes without nicotine (female controls = black, female e-cigarette without nicotine = red). (d) Gene expression data for males exposed to e-cigarettes without nicotine (male controls = black, male e-cigarette without nicotine = red).
Figure 3Quantity of overlapping and unique genes between treatment groups and sex. The Venn diagram displays overlapping and unique genes found to be significantly changed (p < 0.01) via RNA-Seq analysis between treatment groups and sex, as indicated. Diagram created using Venny [19].
Top 5 Ingenuity® Pathway Analysis (IPA) disease and disorder categories for each treatment group and sex compared to sex-matched air controls.
| Ingenuity Disease and Disorders | # of Molecules | |
| Cancer | 5.43 E−05–2.09 E−28 | 1157 |
| Organismal Injury and Abnormalities | 7.31 E−05–2.09 E−28 | 1162 |
| Neurological Disease | 7.75 E−05–1.78 E−27 | 484 |
| Psychiatric Disorders | 7.00 E−05–1.33 E−22 | 320 |
| Gastrointestinal Disease | 5.85 E−05–1.26 E−21 | 838 |
| Ingenuity Disease and Disorders | # of Molecules | |
| Cancer | 6.03 E−06–3.98 E−46 | 2121 |
| Organismal Injury and Abnormalities | 6.82 E−06–3.98 E−46 | 2130 |
| Neurological Disease | 8.19 E−06–1.55 E−35 | 811 |
| Gastrointestinal Disease | 6.03 E−06–3.33 E−35 | 1553 |
| Psychiatric Disorders | 8.19 E−06–5.77 E−31 | 537 |
| Ingenuity Disease and Disorders | # of Molecules | |
| Cancer | 1.38 E−02–2.18 E−12 | 137 |
| Organismal Injury and Abnormalities | 1.38 E−02–2.18 E−12 | 137 |
| Dermatological Diseases and Conditions | 6.92 E−03–9.47 E−11 | 80 |
| Connective Tissue Disorders | 6.92 E−03–1.73 E−10 | 83 |
| Gastrointestinal Disease | 1.38 E−02–7.37 E−06 | 99 |
| Ingenuity Disease and Disorders | # of Molecules | |
| Cancer | 2.97 E−06–2.20 E−35 | 2096 |
| Organismal Injury and Abnormalities | 2.97 E−06–2.20 E−35 | 2108 |
| Neurological Disease | 3.27 E−06–7.20 E−34 | 814 |
| Gastrointestinal Disease | 1.10 E−06–1.27 E−30 | 1516 |
| Psychiatric Disorders | 3.27 E−06–1.34 E−27 | 510 |
The number of molecules, calculated from the gene expression data, indicates how many molecules/genes in the disease/disorder pathway were altered. The p-value range indicates the range of significance for the molecules involved in the pathway.
Figure 4Top 50 disease and biological functions predicted to be altered using IPA comparison analysis. Data obtained from RNA-Seq were filtered to only include those results reaching a p < 0.01 significance level; these RNA-Seq data were then imported into IPA for comparison analysis. A positive activation z-score reflects induction of the indicated disease/biological function, while a negative z-score reflects inhibition of the indicated disease/biological function. Z-scores of +/− 2.0 were considered significant.
Comparison of gene expression data from qPCR and RNA-Seq analyses. Gene expression fold-change and p-values for frontal cortex samples recovered from male offspring exposed early in life to e-cigarette aerosols with or without nicotine are compared using qPCR and RNA-Seq.
| Gene | Frontal Cortex Samples from Male Offspring Exposed to E-Cigarettes Containing Nicotine | Frontal Cortex Samples from Male Offspring Exposed to E-Cigarettes Without Nicotine | ||||||
|---|---|---|---|---|---|---|---|---|
| RNA-Seq | qPCR | RNA-Seq | qPCR | |||||
| Fold Change | Adjusted | Fold Change | Fold Change | Adjusted | Fold Change | |||
| Ngfr | 2.37 | 3.94E−3 | 2.82 | NS | 3.16 | 1.57E−6 | 4.36 | 0.05 |
| Chat | 1.88 | 6.38E−4 | 2.17 | NS | 2.66 | 9.71E−11 | 3.31 | NS |
| Bdnf | −1.22 | NS | −0.91 | NS | −1.67 | 1.81E−5 | −1.55 | NS |
| Gdnf | ND | NS | 1.47 | NS | 1.93 | 3.6E−5 | 2.13 | NS |
| Gal | ND | NS | 5.6 | 0.001 | 3.66 | 2.01E−6 | 9.56 | 0.001 |
| Tbr1 | −1.31 | NS | −1.25 | NS | −2.02 | 1.68E−11 | −1.91 | NS |
| Adra1d | −1.47 | NS | −2.21 | NS | −2.29 | 9.86E−5 | −3.05 | 0.05 |
Data from qPCR ( n = 3–6 frontal cortex samples/treatment group; only one pup per litter was used for these studies) was analyzed using a two-way ANOVA and Bonferroni post hoc testing (for treatment factor, F-value: 2.08, degrees of freedom: 2; for gene factor, F-value: 26.6, degrees of freedom: 6). ND = Not Detected, NS = Not Significant.